top of page

Swati Gupta; Patricia Fast; Jennifer Lehrman; Matt Price; LEAP4WA Consortium. Lassa Fever Vaccine Efficacy and Prevention For West Africa (LEAP4WA). 10th EDCTP Forum. October 2021. 

An IAVI-led consortium is advancing a Lassa vaccine candidate based on the recombinant vesicular stomatitis virus (rVSV) platform technology. The vaccine candidate demonstrated 100% efficacy against LASV in a nonhuman primate challenge study. Furthermore, it uses the same technology as Merck’s ERVEBO® vaccine, which has been shown to be safe and efficacious in preventing Ebola virus disease and is licensed in multiple countries.


bottom of page